Thomas Jefferson University

Jefferson Digital Commons
Farber Institute for Neurosciences Faculty
Papers

Farber Institute for Neurosciences

10-18-2012

Severe stress switches CRF action in the nucleus accumbens
from appetitive to aversive.
Julia C Lemos
University of Washington

Matthew J Wanat
University of Washington

Jeffrey S Smith
University of Washington

Beverly A S Reyes
Thomas Jefferson University

Nick
Hollon
FollowGthis
and additional works at: https://jdc.jefferson.edu/farberneursofp
University of Washington
Part of the Psychiatry Commons

Let us know how access to this document benefits you
See next page for additional authors

Recommended Citation
Lemos, Julia C; Wanat, Matthew J; Smith, Jeffrey S; Reyes, Beverly A S; Hollon, Nick G; Van
Bockstaele, Elisabeth J; Chavkin, Charles; and Phillips, Paul E M, "Severe stress switches CRF
action in the nucleus accumbens from appetitive to aversive." (2012). Farber Institute for
Neurosciences Faculty Papers. Paper 14.
https://jdc.jefferson.edu/farberneursofp/14
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Farber Institute for Neurosciences Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Julia C Lemos, Matthew J Wanat, Jeffrey S Smith, Beverly A S Reyes, Nick G Hollon, Elisabeth J Van
Bockstaele, Charles Chavkin, and Paul E M Phillips

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/farberneursofp/14
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Severe stress switches CRF action in the nucleus
accumbens from appetitive to aversive
Julia C. Lemos1,2,3, Matthew J. Wanat1,2, Jeffrey S. Smith2, Beverly A. S. Reyes4, Nick G. Hollon1,2,3, Elisabeth J. Van Bockstaele4,
Charles Chavkin2,3 & Paul E. M. Phillips1,2,3

Stressors motivate an array of adaptive responses ranging from ‘fight
or flight’ to an internal urgency signal facilitating long-term goals1.
However, traumatic or chronic uncontrollable stress promotes
the onset of major depressive disorder, in which acute stressors lose
their motivational properties and are perceived as insurmountable
impediments2. Consequently, stress-induced depression is a
debilitating human condition characterized by an affective shift
from engagement of the environment to withdrawal3. An emerging
neurobiological substrate of depression and associated pathology is
the nucleus accumbens, a region with the capacity to mediate a
diverse range of stress responses by interfacing limbic, cognitive
and motor circuitry4. Here we report that corticotropin-releasing
factor (CRF), a neuropeptide released in response to acute stressors5
and other arousing environmental stimuli6, acts in the nucleus
accumbens of naive mice to increase dopamine release through
coactivation of the receptors CRFR1 and CRFR2. Remarkably,
severe-stress exposure completely abolished this effect without
recovery for at least 90 days. This loss of CRF’s capacity to regulate
dopamine release in the nucleus accumbens is accompanied by a
switch in the reaction to CRF from appetitive to aversive, indicating
a diametric change in the emotional response to acute stressors.
Thus, the current findings offer a biological substrate for the switch
in affect which is central to stress-induced depressive disorders.
CRF initiates neuroendocrine signalling in the hypothalamic–
pituitary–adrenal axis and also regulates neurotransmission directly
through two receptor subtypes, CRF receptor 1 (CRFR1) and CRFR2,
which are distributed widely throughout the brain7,8. In the nucleus
accumbens, CRF facilitates cue-elicited motivation9 and social
bonding10, behaviours that are thought to be mediated by dopamine
transmission11,12. Therefore, we sought evidence for CRF–dopamine
interactions in the nucleus accumbens, first using fluorescent
immunohistochemistry. Dense CRF immunoreactivity was present
throughout the rostro-caudal axis of the nucleus accumbens core
and lateral shell, and in the most rostral portion of the medial shell
in sparsely located large cell bodies (cholinergic interneurons, see
Supplementary Fig. 1) and fibre terminals that were interdigitated with
tyrosine-hydroxylase-immunoreactive fibres that are indicative of
dopamine-containing axons (Fig. 1a). Immunoreactivity for the
CRFR1 receptor displayed punctate staining with co-localization of
tyrosine-hydroxylase immunoreactivity on fibre segments in addition
to localization on cell bodies within the nucleus accumbens (Fig. 1b
and Supplementary Fig. 2). CRFR2 immunoreactivity had a more
diffuse but still punctate pattern of staining, similar to that in other
regions13, with some co-localization with tyrosine-hydroxylase
immunoreactivity (Fig. 1c and Supplementary Fig. 3). Expression of
CRF receptors on subcellular profiles in the nucleus accumbens,
including tyrosine-hydroxylase-positive terminals, was confirmed at
higher spatial resolution using transmission electron microscopy
(Fig. 1d; quantified in Supplementary Table 1). Together, these data

indicate that the localization of CRF and its receptors in the nucleus
accumbens is well-suited for modulation of dopamine release.
To directly test the functional effects of CRF on dopamine release in
the nucleus accumbens, we selectively monitored dopamine release
evoked by a single biphasic electrical pulse (2 ms per phase, 100–
500 mA delivered once per minute) in acute coronal brain slices using
fast-scan cyclic voltammetry at carbon-fibre microelectrodes (Fig. 2a
and Supplementary Fig. 4). Vehicle or CRF (10, 100 or 1,000 nM) was
applied to the slice for 15 min after 5 min of stable baseline, and the
resultant effect was quantified by averaging the evoked dopamine
current in the last 10 minutes. After application of vehicle, there was
a modest (,7%) decrease in dopamine release (Fig. 2b), whereas CRF
increased dopamine release in a concentration-dependent manner
eliciting effects significantly greater than vehicle at 100 and
1,000 nM (27.8 6 6.7 and 30.0 6 8.4%, respectively, mean 6 s.e.m.;
F3, 49 5 5.026, P , 0.01, one-way analysis of variance (ANOVA) with
Dunnett’s post-hoc t-tests; Fig. 2b and Supplementary Fig. 5).
Interestingly, this effect could be blocked by application of either the
selective CRFR1 antagonist, antalarmin (1 mM), or the selective CRFR2
antagonist, anti-sauvagine 30 (ASVG 30; 250 nM), to the slice
beginning 20 min before CRF application (F2, 50 5 5.142, P , 0.01,
one-way ANOVA with Dunnett’s post-hoc t-tests; Fig. 2c) indicating
that coactivation of both receptors is required. Consistently, CRF (10,
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Figure 1 | Cellular localization of CRF peptide, CRFR1 and CRFR2 in the
nucleus accumbens. a–c, Immunoreactivity for CRF peptide (top), CRFR1
(middle) or CRFR2 (bottom) is shown in red and for tyrosine hydroxylase (TH)
is shown in green. Arrows highlight examples of co-localization (yellow in the
merged images). Scale bars, 10 mm. d, Transmission electron microscopy
photomicrographs showing CRF receptors (labelled with immunogold
particles; arrows) present on both TH-positive (immunoperoxidase labelled)
and TH-negative profiles. Scale bars, 0.5 mm (top panel) and 1 mm (bottom
panels).
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Figure 2 | CRF increases dopamine release in the nucleus accumbens
through coactivation of CRFR1 and CRFR2. a, Representative dopamine
release evoked by electrical stimulation (dashed lines) before (left) and after
(right) application of 100 nM CRF (mean 6 s.e.m. for 5 consecutive
stimulations, top) and corresponding two-dimensional plots depicting changes
in faradaic current (pseudocolour) with time as the abscissa and applied
potential as the ordinate (bottom). b, Concentration response to CRF, n 5 11–
18. c, Effect of antagonists for CRFR1 (antalarmin, 1000 nM) or CRFR2 (antisauvagine 30 (ASVG 30), 250 nM), n 5 18–20. d, CRF in mice lacking the gene
encoding the CRFR1 (left) or CRFR2 (right) receptors, n 5 7–13. e–g, Effect of
the CRFR1 agonist, stressin 1, n 5 9–15 (e), the CRFR2 agonist, urocortin 3
(100 or 300 nM), n 5 5–8 (f) or their co-application, n 5 8–15 (g). Error bars,
s.e.m. DA, dopamine; NS, not significant (with P . 0.05); *P , 0.05;
**P , 0.01 versus vehicle.

100, 1,000 nM) failed to increase dopamine release in the nucleus
accumbens of mice with deletion of either the Crfr1 (ref. 14) or Crfr2
(ref. 15) gene (Fig. 2d). Application of the selective CRFR1 agonist
stressin 1 (100 or 300 nM) or the selective CRFR2 agonist urocortin
3 (100 or 300 nM) failed to significantly increase dopamine release
when applied individually (P . 0.05 compared to respective vehicles;
Fig. 2e, f), but significantly increased dopamine release when applied
together (F3,36 5 3.528, P , 0.05 versus vehicle, one-way ANOVA with
Dunnett’s post-hoc t-tests). The effect of the agonists together could be
blocked by pre-treatment with antalarmin and ASVG 30 (unpaired
t-test, P . 0.05; Fig. 2g). Together these data provide convergent evidence that CRF increases dopamine release in the nucleus accumbens
through coactivation of CRFR1 and CRFR2.
If this ability for CRF to positively regulate dopamine in the nucleus
accumbens has specific motivational relevance to the behaving animal,
we would predict that it would cause conditioned place preference
when restricted to the nucleus accumbens, even though centrally
administered CRF elicits robust conditioned place aversion16.
Therefore, we used a balanced place-conditioning apparatus consisting of two visually distinct test chambers separated by a smaller neutral
compartment. On day one, mice were allowed to freely roam the
apparatus, and the time they spent in each chamber was recorded.

On days two and three, mice received CRF bilaterally into the nucleus
accumbens (500 ng per side in 200 nl artificial cerebrospinal fluid;
cannulae placements are shown in Supplementary Fig. 6) or vehicle
infusions and were then isolated in one of the test chambers for 30 min.
Four hours later they received the alternative infusion and were isolated in the other test chamber for 30 min. On day four, mice were
again allowed free access to the apparatus. Following conditioning,
mice exhibited a significant preference for the CRF-paired context,
demonstrating that intra-accumbens CRF (500 ng) was an appetitive
stimulus to these animals (conditioning by drug, F1,12 5 6.435,
P , 0.001, two-way repeated-measures ANOVA; Fig. 3a). Similarly,
unilateral infusions of CRF (500 ng in 200 nl) also produced conditioned
place preference (conditioning by drug, F1,12 5 11.77, P , 0.001 twoway repeated-measures ANOVA; Fig. 3b and Supplementary Fig. 7a).
This dose of CRF is within the range that produces selective effects in
vivo9, but it is difficult to ascertain the steady-state concentration at
receptors as CRF undergoes both radial diffusion and active clearance17.
Nevertheless, even at a lower dose of CRF (5 ng in 200 nl), conditioned
place preference was observed (conditioning by drug, F1,14 5 5.415,
P , 0.05, two-way repeated-measures ANOVA; Fig. 3b and
Supplementary Fig. 7b). Taken together, these data indicate that CRF
acts in the nucleus accumbens to produce a positive affective state.
To test whether this positive affective state is dependent upon CRF’s
ability to increase dopamine release, we used the catecholaminergicneuron-selective neurotoxin, 6-hydroxydopamine (6-OHDA). We
compared unilateral CRF place conditioning in animals that had
received ipsilateral infusions of 6-OHDA (2 mg in 500 nl) versus
vehicle (0.09% NaCl, 0.1% ascorbate) into the nucleus accumbens
7 days earlier. CRF (500 ng in 200 nl) produced place preference in
sham animals (conditioning by drug, F1,18 5 6.95, P , 0.05 two-way
repeated-measures ANOVA; Supplementary Fig. 8a), of similar
magnitude to controls (treatment by drug, F1,30 5 0.35, P . 0.05,
two-way ANOVA). However, place preference to intra-accumbens
CRF was absent in animals that received 6-OHDA (conditioning by
drug, F1,18 5 0.00, P . 0.05, two-way repeated-measures ANOVA;
Supplementary Fig. 8b) showing a significant change in the subjective
effects of CRF (P , 0.05, unpaired t-test; Fig. 3b). This 6-OHDA
treatment produced a significant dopamine depletion on the side of
the injection (P , 0.001; Supplementary Fig. 8c), but did not alter
locomotor activity (P . 0.05, unpaired t-test; Supplementary Fig. 8d),
demonstrating that the unilateral lesions did not produce a general
deficit in motor function. These data demonstrate that the positive
affective state produced by CRF in the nucleus accumbens is dependent
on its ability to increase dopamine release.
To ascertain the role of endogenously released CRF in the nucleus
accumbens in mediating appetitive behaviours, we tested the effect of
CRF antagonism on the response to an arousing stimulus by assaying
novel object exploration, a behaviour that requires intact dopamine
transmission18. We bilaterally infused the CRF antagonist, a-helical
CRF (500 ng in 200 nl per side) or vehicle (lactated ringer’s with 1%
acetic acid), into the nucleus accumbens, placed animals into an arena,
and then 15 min later introduced a novel object into the centre.
Although a-helical CRF had no effect on baseline exploration of the
centre of the arena compared to vehicle, it significantly attenuated
the appetitive effects (that is, eliciting of approach and exploration)
of the novel object (treatment by stimulus, F1,18 5 4.62, P , 0.05,
two-way repeated-measures ANOVA; Fig. 3c). These data demonstrate that endogenous CRF in the nucleus accumbens is used under
physiological conditions to mediate appetitive responses to arousing
environmental stimuli.
Exposure to severe or chronic stress can produce profound alterations in normal stress signalling that can be detrimental to physical and
mental health, predisposing individuals to depression19. To model this
phenomenon, we used a modified Porsolt paradigm in which mice are
exposed to 2 days of repeated swim stress. Animals were placed in a
vessel of water (29–31 uC) for 15 min followed by four additional
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Figure 3 | CRF in the nucleus accumbens promotes appetitive behaviour.
a, Mean difference in times spent in the CRF-paired chamber compared to the
vehicle-paired chamber before and after conditioning (top panel; n 5 7 ) and
representative post-conditioning activity trace (bottom panel). b, Place
preference (time in CRF-paired chamber minus the time spent in the vehiclepaired chamber post conditioning) for intra-nucleus accumbens injections of
500 ng CRF bilateral, 500 ng unilateral or 5 ng bilateral (left panel; n 5 7–10).

Place preference for 500 ng CRF (unilateral) in sham or 6-OHDA-treated mice
(right; n 5 10). c, Time spent in the centre of an open field before and during
presentation of a novel object (placed in the centre of the field) after bilateral
intra-accumbens infusion of the CRF-receptor antagonist a-helical CRF
(500 ng) or its vehicle (n 5 10). Error bars, s.e.m. NS, P . 0.05; *P , 0.05;
**P , 0.01; ***P , 0.001; 1P , 0.05 for interaction.

6-min swim sessions (separated by 6-min recovery periods) 24 h later.
This protocol has been shown to produce escalating immobility across
sessions, indicating a depression-like phenotype20. We prepared coronal
slices of the nucleus accumbens from these animals 30 minutes after the
final stress exposure and found that the ability for CRF to potentiate
dopamine release was completely abolished (stress exposure by drug,
F4,116 5 12.61, P , 0.001 two-way ANOVA; Fig. 4a). Notably, we
established that this change in the ability of CRF to regulate dopamine
release was not a generalized change in stress-related peptide signalling
as the effect of a k-opioid agonist to reduce dopamine release was
unaffected by the 2-day stress-exposure paradigm (Supplementary
Fig. 9). Therefore, these data show that severe stress selectively
abolishes CRF’s ability to modulate dopamine release in the nucleus
accumbens. Surprisingly, there was no recovery of the action of CRF on
dopamine release in the nucleus accumbens 7, 30 or even 90 days
after stress exposure (stress exposure by drug, F4,116 5 4.852, P
, 0.01, two-way ANOVA; Fig. 4a). This time period is consistent with
the protracted course of stress-induced depressive disorders21, and
indeed, a depression-like phenotype was maintained across this
90-day post-stress period, as assessed by swim immobility (Supplementary Fig. 10). Importantly, the loss of the CRF response was
not due to a baseline change in evoked dopamine release (Supplementary Fig. 11) and it was not simply an age-related phenomenon
(Supplementary Fig. 12). Therefore, we have shown that severe stress
produces a persistent dysregulation of CRF-dopamine interactions
that normally produce a positive affective state.
Stress-induced depressive disorders are associated with altered
levels of several neurochemicals that interact with the CRF system,
including serotonin22, dynorphin23 and glucocorticoids4,24. Therefore,
we targeted these systems to gain mechanistic insight into the stressinduced loss of CRF’s regulation of dopamine release. We pretreated

animals (10 ml kg21 intraperitoneal) with vehicle, fluoxetine (selective
serotonin-reuptake inhibitor; 10 mg kg21), norBNI (k-opioid-receptor
antagonist; 10 mg kg21) or RU486 (glucocorticoid-receptor antagonist;
30 mg kg21) before stress exposure on each of the swim-stress days.
The animals were allowed to recover for 7 days, then slices were
prepared and the CRF response was tested. Although acute regimens
of fluoxetine do not alleviate pre-existing depression-related symptoms
in patients or animal models, they have been shown to prevent the
induction of some depression-like responses to stress25. Nevertheless,
this treatment did not affect the abolition of CRF modulation of
dopamine release by stress (P . 0.05; Supplementary Fig. 13).
Similarly, this stress-induced perturbation was not significantly
affected by norBNI (P . 0.05; Supplementary Fig. 13); however, it
was prevented by RU486 (30 mg kg21; P , 0.001; Fig. 4a and Supplementary Fig. 13), even at a lower dose (10 mg kg21; P , 0.01;
Supplementary Fig. 13). These data show that glucocorticoid signalling
is a critical component of the profound stress-induced dysregulation of
CRF–dopamine interactions in the nucleus accumbens.
This robust loss of the neurochemical response to CRF in the
nucleus accumbens after severe stress suggests a long-lasting alteration in its subjective qualities. To test this idea, we used the placeconditioning paradigm in animals that had been exposed to the
2-day swim-stress regimen. Mice that underwent repeated swim stress
7 days before conditioning spent significantly less time in the CRFpaired chamber than in the vehicle-paired chamber after conditioning,
establishing that CRF in the nucleus accumbens is now aversive to
these animals (conditioning by drug, F1, 10 5 5.824, P , 0.01, twoway ANOVA, Supplementary Fig. 14a). Therefore, severe stress
produces a diametric shift in the subjective qualities of CRF in the
nucleus accumbens from positive to negative (Fig. 4b). Consistent with
the enduring loss of CRF regulation of dopamine observed in vitro, the
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absence of CRF conditioned place preference persisted for at least
90 days after repeated stress exposure (F2,20 5 6.870, P , 0.05, oneway ANOVA with Dunnett’s post hoc; Fig. 4b and Supplementary
Fig. 14b). Similarly, endogenously released CRF no longer stimulated
exploration of a novel object when tested 7 days after stress exposure
(stimulus by drug, F1,16 5 0.004, P . 0.05, two-way repeated-measures
ANOVA; Supplementary Fig. 15) showing that severe stress abolished
the function of CRF in the nucleus accumbens to stimulate appetitive
responses to arousing stimuli (unpaired t-test, P , 0.05, Fig. 4c).
Therefore, these findings demonstrate the long-term loss of a regulatory mechanism of motivated behaviour after severe stress.
Major depressive disorder has a lifetime prevalence of 17%, making
it one the world’s greatest public-health concerns26; however, its
molecular foundation has been elusive. Patients suffering from this
disorder present with constellations of symptoms that include loss of
affect, cognitive impairment and homeostatic imbalance27; symptoms
that are presumably precipitated by dysregulation of several brain
regions4. It is established that glucocorticoid-dependent hippocampal
atrophy is a critical mediator of cognitive impairment in depression such as memory loss4. More recently, disruption of nucleus
accumbens function has been implicated in the affective symptoms
of depression4. In the current work, we studied the actions of CRF on
neurotransmission within this brain region in an attempt to connect
pathological stress-related neuroadaptation with the shift in affect
observed in depressed patients.
CRF receptors are distributed widely throughout the brain8 and
mediate disparate effects (see Supplementary Discussion). Our data
highlight the specificity of the local action of both exogenously applied
and endogenously released CRF in the nucleus accumbens in producing a positive, rather than negative, subjective state by increasing
dopamine release. Importantly, we show that severe stress disables this

Subjects. Male C57BL/6 mice aged .50 days had ad libitum access to food and
water. Mice housed together (two to four per cage) were subjected to the same
behavioural treatments. All animal procedures were approved by the University of
Washington Institutional Animal Care and Use Committee.
Neuroanatomy. Immunohistochemistry was carried out as described previously20. Sections were incubated for 24 h with a mixture of mouse anti-tyrosine
hydroxylase 1:1,000 and rabbit anti-CRF (peptide) 1:150, and chicken anti-ChAT
antibody 1:150 or rabbit anti-CRFR1 or goat anti-CRFR2 (1:100 to 1:500), then
incubated in the appropriate fluorescently tagged secondary antibodies (1:500),
and were imaged using epifluorescent and confocal microscopes. Transmission
electron microscopy was carried out as previously described30.
Fast-scan cyclic voltammetry. 250-mm coronal slices containing the nucleus
accumbens were continuously perfused (1.5–2.0 ml min21) with oxygenated
artifical cerebrospinal fluid (aCSF) maintained at 31–33 uC. The potential at a
carbon-fibre electrode was held at 20.4 V versus Ag/AgCl, ramped to 11.3 V
and back to 20.4 V (400 V s21) every 100 ms. A single biphasic electrical pulse
(2 ms per phase, 100–500 mA) was applied to the slice to evoke dopamine release.
Conditioned place preference. A three-compartment place-conditioning
apparatus was used to measure preference as described previously20. On days 2
and 3, mice received two intra-accumbens microinjections per day: one injection
of aCSF and one injection of CRF (500 ng in 200 nl per side) paired with different
chambers. On day 4, mice were allowed free access to the apparatus for 30 min. At
the end of behavioural testing, cannulae placements were assessed.
Novel-object exploration. The novel object exploration assay was similar to an assay
that has been described previously28. Animals received bilateral intra-accumbens
microinfusions of vehicle or a-helical CRF (500 ng in 200 nl) counterbalanced across
2 days of testing. On each testing day, the animal was exposed to a new novel object.
Full Methods and any associated references are available in the online version of
the paper.
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Published online 19 September; corrected online 17 October 2012 (see full-text
HTML for details).
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METHODS
Subjects. Male C57BL/6 mice aged .50 days were maintained under a 12-h light–
dark cycle (7:00 to 19:00 light) with access to standard food and water ad libitum.
All procedures on animal subjects were approved by the University of Washington
or Thomas Jefferson University Institutional Animal Care and Use Committee.
Mice housed together (two to four per cage) were subjected to the same behavioural treatments.
Immunohistochemistry. We used perfusion, cryosectioning and immunohistochemistry procedures as described previously20. Sections (30 mm) were then incubated with a mixture of mouse anti-tyrosine hydroxylase 1:1,000 (Sigma) and
either rabbit anti-CRF (peptide) 1:150 (Sigma) and chicken anti-ChAT antibody
1:150 (Invitrogen) or rabbit anti-CRFR1 or CRFR2 (Novus Biologicals) in blocking buffer for 24–36 h at room temperature. Sections were then washed with PBS,
and detection was carried out using the fluorescent secondary antibody Alexa
Fluor 488 goat anti-mouse immunoglobulin-G (IgG) 1:500, Alexa Fluor 555 goat
anti-rabbit IgG and Alexa Fluor 633 goat anti-chicken IgG (Invitrogen) in blocking buffer for 2 h at room temperature. Sections were washed in PBS 3 times for
10 min and 0.1 M phosphate buffer twice for 10 min and mounted on Superfrost
plus slides. Sections were imaged with epifluorescence (Nikon) and confocal
microscopes (Leica).
Transmission electron microscopy. Mice were perfused and brains were
sectioned as described previously. Sections (100 nm) were processed using
standard transmission-electron-microscopy procedures30,31. Sections were incubated in mouse anti-TH (1:1,000; Immunostar) and rabbit anti-corticotropinreleasing factor receptor (1:1,000; Santa Cruz Biotechnology) overnight at room
temperature. Immunoperoxidase detection of tyrosine hydroxylase and silverintensified immunogold localization of CRFRs followed standard procedures30.
Digital images were captured using the AMT advantage HR/HR-B CCD camera
system (Advance Microscopy Techniques). Only tissue sections with good
preservation of ultrastructural morphology and with both tyrosine hydroxylase
and CRFR immunoreactivity clearly apparent in the tissue were used for the
analysis. For immunogold labelling, profiles with at least two immunogold-silver
particles within a cellular compartment in a single thin section were considered
immunolabelled30,32. The cellular elements were classified according to a method
described previously33,34.
Fast-scan cyclic voltammetry. Mice were quickly decapitated and the head placed
in pre-oxygenated ice-cold artificial cerebrospinal fluid (aCSF) in which sucrose
(248 mM) was substituted for NaCl. The brain was rapidly removed and blocked
to isolate the anterior forebrain. Coronal slices (250 mm) containing the nucleus
accumbens were prepared using methods described previously35, placed in a
recording chamber and continuously perfused (1.5–2.0 ml min21) with oxygenated
aCSF (in mM: NaCl, 124; KCl, 2.5; NaH2PO4, 1.25; MgSO4, 2.0; CaCl2, 2.0; dextrose,
10; and NaHCO3, 26) maintained at 31–33 uC. Carbon-fibre electrodes were
fabricated using a Sutter P-97 puller. Carbon-fibre electrodes (working electrodes)
were hand cut to approximately 100–150 mm past the capillary tip. The potential at
a carbon-fibre electrode was held at 20.4 V versus Ag/AgCl, ramped to 11.3 V
and back to 20.4 V (400 V s21) every 100 ms. A single biphasic electrical pulse
(2 ms per phase, 100–500 mA) was applied to the slice to evoke dopamine release.
Swim stress. Mice were subjected to either a single 15-min swim with a 24-h
recovery period, or a 2-day swim stress in which they were exposed to a 15-min
swim session on day 1, then 24 h later on day 2, were exposed to 4 swim sessions of
6 min separated by 6 min, conducted under bright light (690–700 lx) conditions.
Water temperature was maintained at 29–31 uC. Animals were removed from the
water if they became completely submerged for .1 s at any time during the
paradigm. Some animals were killed at 30 min, 7, 30 or 90 days after the final swim
session of the 2-day protocol, and nucleus accumbens slices were prepared.

Cannulations. Animals were anaesthetized with isoflurane and cannulation
surgeries were carried out using a stereotaxic alignment system, similar to
methods described previously20. Double-guide cannulas (26 gauge, 3.5 mm from
pedestal, 2 mm separation; Plastics One) were placed in the nucleus accumbens
core at 61 mm lateral, 1 mm posterior from bregma and 3.5 mm below the
skull. Guide cannulas were anchored using dental cement, and dummy
internal cannulas were placed inside until injection. Mice were injected
intracerebroventricularly by placing a 33-gauge internal cannula (Plastics One)
into the guide cannula.
Conditioned place preference. Animals were allowed to recover from surgery for
at least 7 days. All animals were handled for 4 days before the pre-test day. Animals
assigned to the stress-exposed group were subjected to the 2-day swim-stress
paradigm after recovery; animals were not included if they did not show normal
swimming responses. Stress-exposed animals began CRF conditioning 7 or
90 days after the final swim session. A three-compartment place-conditioning
apparatus was used to measure preference as described previously20. On days 2
and 3, mice received 2 injections per day: 1 injection of aCSF and 1 injection of
CRF (500 ng per 200 nl) paired with different chambers at 125 nl min21. On day 4,
mice were once again allowed free access to the entire apparatus for 30 min. After
the conclusion of behavioural testing, cannulae placements were assessed. Mice
with cannula placements outside the accumbens were excluded from the study.
6-OHDA lesion and high-performance liquid chromatography. Mice were
injected with either 6-OHDA (2 mg per 500 nl; Sigma) or vehicle (0.9% NaCl,
0.1% ascorbate). After the conclusion of behavioural testing, a tissue core (approximately 2 3 2 3 1 mm) of the ipsilateral and contralateral accumbens of each animal
was microdissected, rapidly frozen in liquid nitrogen and stored in microcentrifuge
tube at 280 uC until processed for tissue dopamine content. High-performance
liquid chromatography (HPLC) was used to measure monoamine content by the
Neurochemistry Core Laboratory at the Vanderbilt University Center for
Molecular Neuroscience Research.
Novel object exploration. Mice were cannulated, allowed to recover from
surgery and handled for 4 days before being subjected to a novel object exploration
assay similar to previously described28. In brief, on test day 1, mice were given
bilateral intra-accumbens microinfusions of either vehicle (lactated ringer’s with
1% acetic acid) or a-helical CRF (2 mg) and were allowed to habituate in an open
field for 15 min. Subsequently, a novel object was introduced and exploratory
behaviour of the novel object was measured for an additional 15 min. On test
day 2, the animals received the alternative pharmacological treatment to that
which they received on day 1, were allowed to habituate again in the open field
and then exposed to a second novel object. Both the pharmacological treatment
and the novel objects were counter-balanced across test days. Identically to the
place-conditioning experiments, 1 group of mice were exposed to swim stress
7 days before test day 1.
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